2 completed, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow MVA-BN-Brachyury: new trials by email Literature Review of MVA-BN-Brachyury trials Research Report on MVA-BN-Brachyury
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer MVA-BN-Brachyury - Solid Metastatic Tumor | Phase 1 | Completed | Bavarian Nordic | 13 | 2020-01-08 | 2021-07-14 |
| Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer MVA-BN-Brachyury - Prostate Adenocarcinoma | Phase 2 | Withdrawn | University of Utah | 2019-11-20 | 2021-09-22 | |
| Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) M7824, N-803, MVA-BN-Brachyury - Metastatic Castration-resistant Prostate Cancer, Prostate Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 59 | 2018-05-01 | 2025-09-30 |
Bavarian Nordic (1) · National Cancer Institute (NCI) (1) · University of Utah (1)
United States (3)
James L Gulley, M.D. (1) · Marijo Bilusic, MD,PhD (1)
PMID 30227893, PMID 33602696, PMID 34266694, PMID 34479925, PMID 42498485